Neoadjuvant Chemo New SOC Option in Urothelial Carcinoma

Neoadjuvant chemotherapy in the high-risk population demonstrated favorable pathologic responses, and was well tolerated.

Related Keywords

Pennsylvania ,United States ,Fox Chase ,Philadelphia ,San Francisco ,California ,Daniel Geynisman , ,Cancers Symposium ,Fox Chase Cancer Center ,Medscape Medical ,Bladder Cancer ,Alignant Bladder Neoplasm ,Cancer ,Alignant Neoplasia ,Arcinoma ,Neoadjuvant ,Chemotherapy ,Transitional Cell Carcinoma ,Surgery ,Tolerance ,Drug Induced Toxicity ,Hyperglycemia ,Lymph Node Dissection ,Lymphedema ,Lymphoedema ,Ymphatic Obstruction ,Neutropenia ,